Role of EMT (epithelial mesenchymal transition) in metastatic breast cancer: Association with eribulin and cyclin dependent kinase inhibitor treatment and disease recurrence
- Conditions
- Breast CancerCancer - Breast
- Registration Number
- ACTRN12621000199819
- Lead Sponsor
- Breast Cancer Research Centre - WA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 252
a) Consent to use of tumour tissue
b) Histologically confirmed BC with archived primary BC tissue available
c) Diagnosis of metastatic BC where histological confirmation has been
confirmed in patient with de novo metastatic BC or histological/ cytological /
unequivocal radiologic diagnosis of metastatic disease in a patient with prior
diagnosis breast cancer
d) Patients with hormone receptor positive, HER2 negative BC who have (i)
received a cyclin D kinase inhibitor in the adjuvant setting and who has
experienced a BC recurrent event or (ii) received a cyclin D kinase inhibitor in
the metastatic setting
e) Any metastatic BC patient who has received at least one dose of eribulin in
the course of their metastatic BC
a) Non-breast metastatic malignancy after BC diagnosis
b) Lost to follow-up (incomplete data in medical records and/or PI's secure database to provide adequate information)
c) Inadequate tumour tissue for biomarker analysis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method